PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 26626348-2 2016 INTRODUCTION: Cobalamin/Vitamin B12 (Cbl) is an essential vitamin, supplied mainly as hydroxocobalamin (OHCbl) by animal products, including cows" milk. Hydroxocobalamin 86-102 Cbl proto-oncogene Bos taurus 14-35 26626348-2 2016 INTRODUCTION: Cobalamin/Vitamin B12 (Cbl) is an essential vitamin, supplied mainly as hydroxocobalamin (OHCbl) by animal products, including cows" milk. Hydroxocobalamin 86-102 Cbl proto-oncogene Bos taurus 37-40 26626348-2 2016 INTRODUCTION: Cobalamin/Vitamin B12 (Cbl) is an essential vitamin, supplied mainly as hydroxocobalamin (OHCbl) by animal products, including cows" milk. Hydroxocobalamin 104-109 Cbl proto-oncogene Bos taurus 14-35 26626348-2 2016 INTRODUCTION: Cobalamin/Vitamin B12 (Cbl) is an essential vitamin, supplied mainly as hydroxocobalamin (OHCbl) by animal products, including cows" milk. Hydroxocobalamin 104-109 Cbl proto-oncogene Bos taurus 37-40 25978498-7 2016 CONCLUSION: Treatment with hydroxocobalamin in combination with betaine appears to be useful for hematological improvement and prevention of brain disabilities in CblE-affected patients. Hydroxocobalamin 27-43 5-methyltetrahydrofolate-homocysteine methyltransferase reductase Homo sapiens 163-167 26989453-4 2016 MS activity was dependent upon methylcobalamin (MeCbl) or the combination of hydroxocobalamin (OHCbl) and S-adenosylmethionine (SAM). Hydroxocobalamin 77-93 5-methyltetrahydrofolate-homocysteine methyltransferase Homo sapiens 0-2 26638881-8 2016 Apparent permeability coefficients of coenzyme B12, hydroxocobalamin, methylcobalamin and 4-ethylphenylcobalamin were 10.2, 0.3, 9.4 and 31.3 fold of vitamin B12 on Caco-2 cells while 0.2, 0.4, 2.6 and 1.9 fold of vitamin B12 on rat intestine, respectively. Hydroxocobalamin 52-68 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 158-161 26638881-8 2016 Apparent permeability coefficients of coenzyme B12, hydroxocobalamin, methylcobalamin and 4-ethylphenylcobalamin were 10.2, 0.3, 9.4 and 31.3 fold of vitamin B12 on Caco-2 cells while 0.2, 0.4, 2.6 and 1.9 fold of vitamin B12 on rat intestine, respectively. Hydroxocobalamin 52-68 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 158-161 25139746-6 2014 The inhibitory actions of SNAP and 8-Br-cGMP on 11,12-EET-induced membrane hyperpolarization and vascular relaxation were reversed by hydroxocobalamin, an NO scavenger; ODQ, a guanylyl cyclase inhibitor; and KT5823, a protein kinase G (PKG) inhibitor. Hydroxocobalamin 134-150 protein kinase cGMP-dependent 1 Homo sapiens 218-234 25139746-6 2014 The inhibitory actions of SNAP and 8-Br-cGMP on 11,12-EET-induced membrane hyperpolarization and vascular relaxation were reversed by hydroxocobalamin, an NO scavenger; ODQ, a guanylyl cyclase inhibitor; and KT5823, a protein kinase G (PKG) inhibitor. Hydroxocobalamin 134-150 protein kinase cGMP-dependent 1 Homo sapiens 236-239 25994134-5 2015 All acyl-Cbls underwent the Co-C bond cleavage upon photo-irradiation with a tungsten light bulb as well as upon treatment with alkali, forming aquacobalamin (aqCbl) and hydroxocobalamin (OH-Cbl), respectively, under air. Hydroxocobalamin 170-186 Cbl proto-oncogene Homo sapiens 9-12 24855323-5 2014 NO-Cbl, synthesized from hydroxocobalamin and pure nitric oxide gas, was subjected to degradative stress conditions including oxidation, hydrolysis and thermal and radiant energy challenge. Hydroxocobalamin 25-41 Cbl proto-oncogene Equus caballus 3-6 24690283-0 2014 Long-lasting atypical acneiform eruption with prominent comedones induced by hydroxocobalamin (vitamin B12 ). Hydroxocobalamin 77-93 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 103-106 24787693-8 2014 L-NAME attenuated the potency of CNP and similar results were obtained in the presence of hydroxocobalamin, an intracellular NO0 scavenger. Hydroxocobalamin 90-106 natriuretic peptide C Rattus norvegicus 33-36 24422907-2 2014 This study aimed to test the hypothesis that in patients with serum B12 < 300 pmol/L, intramuscular hydroxocobalamin reduces erythropoietin requirements whilst maintaining haemoglobin concentrations (Hb). Hydroxocobalamin 103-119 erythropoietin Homo sapiens 128-142 24575711-12 2014 We demonstrated that TNF was consistently detected and IFN-gamma and IL-2 sporadically detected in the TMJ synovial fluid of healthy individuals using the hydroxocobalamin method and a multiplex assay. Hydroxocobalamin 155-171 tumor necrosis factor Homo sapiens 21-24 24422907-11 2014 CONCLUSIONS: In HD patients with B12 < 300 pmol/L, following treatment with hydroxocobalamin there was reduced erythropoietin requirements, maintained Hb and a small but significant rise in the serum albumin. Hydroxocobalamin 79-95 erythropoietin Homo sapiens 114-128 24330302-7 2013 The observed homozygous p.P86L mutation in the N-terminal extended segment may yield reduced MCM activity and is refractory to hydroxocobalamin supplementation, while not inducing a metabolically unstable phenotype. Hydroxocobalamin 127-143 methylmalonyl-CoA mutase Homo sapiens 93-96 23924851-3 2013 Results show pink-colored product generated during manufacturing is due to association of hydroxocobalamin (OH-Cbl), a form of vitamin B12. Hydroxocobalamin 90-106 Cbl proto-oncogene Homo sapiens 111-114 23825108-2 2013 In cblG, mutations in methionine synthase (MTR) decrease conversion of hydroxocobalamin (HOCbl) to methylcobalamin, while in cblC, mutations in MMACHC disrupt formation of cob(II)alamin (detected as HOCbl). Hydroxocobalamin 71-87 5-methyltetrahydrofolate-homocysteine methyltransferase Homo sapiens 22-41 23825108-2 2013 In cblG, mutations in methionine synthase (MTR) decrease conversion of hydroxocobalamin (HOCbl) to methylcobalamin, while in cblC, mutations in MMACHC disrupt formation of cob(II)alamin (detected as HOCbl). Hydroxocobalamin 90-95 5-methyltetrahydrofolate-homocysteine methyltransferase Homo sapiens 22-41 23825108-2 2013 In cblG, mutations in methionine synthase (MTR) decrease conversion of hydroxocobalamin (HOCbl) to methylcobalamin, while in cblC, mutations in MMACHC disrupt formation of cob(II)alamin (detected as HOCbl). Hydroxocobalamin 90-95 metabolism of cobalamin associated C Homo sapiens 145-151 23825108-2 2013 In cblG, mutations in methionine synthase (MTR) decrease conversion of hydroxocobalamin (HOCbl) to methylcobalamin, while in cblC, mutations in MMACHC disrupt formation of cob(II)alamin (detected as HOCbl). Hydroxocobalamin 200-205 5-methyltetrahydrofolate-homocysteine methyltransferase Homo sapiens 22-41 23825108-2 2013 In cblG, mutations in methionine synthase (MTR) decrease conversion of hydroxocobalamin (HOCbl) to methylcobalamin, while in cblC, mutations in MMACHC disrupt formation of cob(II)alamin (detected as HOCbl). Hydroxocobalamin 200-205 metabolism of cobalamin associated C Homo sapiens 145-151 23825108-4 2013 In four "cblG-variant" cases, we observed a decreased conversion of cyanocobalamin to HOCbl that is also seen in cblC cases. Hydroxocobalamin 86-91 Cbl proto-oncogene C Homo sapiens 113-117 23635811-2 2013 Co-oximetry may also be affected by hydroxocobalamin, leading to false elevations in hemoglobin concentration, methemoglobin, carboxyhemoglobin, and false decreases in oxyhemoglobin. Hydroxocobalamin 36-52 hemoglobin subunit gamma 2 Homo sapiens 111-124 23764205-0 2013 Optimizing the dose of hydroxocobalamin in cobalamin C (cblC) defect. Hydroxocobalamin 23-39 Cbl proto-oncogene C Homo sapiens 43-54 23764205-0 2013 Optimizing the dose of hydroxocobalamin in cobalamin C (cblC) defect. Hydroxocobalamin 23-39 Cbl proto-oncogene C Homo sapiens 56-60 23415655-6 2013 We demonstrate that a complex between CblC and CblD can be isolated particularly under conditions that permit dealkylation of alkylcobalamin by CblC or in the presence of the corresponding dealkylated and oxidized product, hydroxocobalamin (HOCbl). Hydroxocobalamin 223-239 Cbl proto-oncogene C Homo sapiens 38-42 23415655-6 2013 We demonstrate that a complex between CblC and CblD can be isolated particularly under conditions that permit dealkylation of alkylcobalamin by CblC or in the presence of the corresponding dealkylated and oxidized product, hydroxocobalamin (HOCbl). Hydroxocobalamin 223-239 metabolism of cobalamin associated D Homo sapiens 47-51 23415655-6 2013 We demonstrate that a complex between CblC and CblD can be isolated particularly under conditions that permit dealkylation of alkylcobalamin by CblC or in the presence of the corresponding dealkylated and oxidized product, hydroxocobalamin (HOCbl). Hydroxocobalamin 241-246 Cbl proto-oncogene C Homo sapiens 38-42 23415655-6 2013 We demonstrate that a complex between CblC and CblD can be isolated particularly under conditions that permit dealkylation of alkylcobalamin by CblC or in the presence of the corresponding dealkylated and oxidized product, hydroxocobalamin (HOCbl). Hydroxocobalamin 241-246 metabolism of cobalamin associated D Homo sapiens 47-51 23415655-10 2013 Our results are consistent with an adapter function for CblD, which in complex with CblC HOCbl, or possibly the less oxidized CblC cob(II)alamin, partitions the cofactor between AdoCbl and MeCbl assimilation pathways. Hydroxocobalamin 89-94 metabolism of cobalamin associated D Homo sapiens 56-60 23415655-10 2013 Our results are consistent with an adapter function for CblD, which in complex with CblC HOCbl, or possibly the less oxidized CblC cob(II)alamin, partitions the cofactor between AdoCbl and MeCbl assimilation pathways. Hydroxocobalamin 89-94 Cbl proto-oncogene C Homo sapiens 84-88 23241609-7 2013 Supplementation of cultured MMACHC-mutant cells with hydroxocobalamin (HOCbl) failed to restore these variants to the normal phenotype, suggesting that a defective Cbl processing pathway produces irreversible changes at the protein level. Hydroxocobalamin 53-69 Cbl proto-oncogene Homo sapiens 73-76 23781123-6 2013 In resolution, 24 h after LPS, HOCbl completely abrogates a major late mediator of sepsis mortality, high mobility group box 1 (HMGB1) mRNA, inhibits iNOS mRNA, and attenuates LPS-induced hepatic inhibition of eNOS mRNA, whilst showing increased, but still moderate, NOS activity, relative to LPS only. Hydroxocobalamin 31-36 high mobility group box 1 Mus musculus 101-126 23781123-0 2013 Biphasic modulation of NOS expression, protein and nitrite products by hydroxocobalamin underlies its protective effect in endotoxemic shock: downstream regulation of COX-2, IL-1beta, TNF-alpha, IL-6, and HMGB1 expression. Hydroxocobalamin 71-87 cytochrome c oxidase II, mitochondrial Mus musculus 167-172 23781123-0 2013 Biphasic modulation of NOS expression, protein and nitrite products by hydroxocobalamin underlies its protective effect in endotoxemic shock: downstream regulation of COX-2, IL-1beta, TNF-alpha, IL-6, and HMGB1 expression. Hydroxocobalamin 71-87 interleukin 1 beta Mus musculus 174-182 23781123-0 2013 Biphasic modulation of NOS expression, protein and nitrite products by hydroxocobalamin underlies its protective effect in endotoxemic shock: downstream regulation of COX-2, IL-1beta, TNF-alpha, IL-6, and HMGB1 expression. Hydroxocobalamin 71-87 tumor necrosis factor Mus musculus 184-193 23781123-0 2013 Biphasic modulation of NOS expression, protein and nitrite products by hydroxocobalamin underlies its protective effect in endotoxemic shock: downstream regulation of COX-2, IL-1beta, TNF-alpha, IL-6, and HMGB1 expression. Hydroxocobalamin 71-87 interleukin 6 Mus musculus 195-199 23781123-0 2013 Biphasic modulation of NOS expression, protein and nitrite products by hydroxocobalamin underlies its protective effect in endotoxemic shock: downstream regulation of COX-2, IL-1beta, TNF-alpha, IL-6, and HMGB1 expression. Hydroxocobalamin 71-87 high mobility group box 1 Mus musculus 205-210 23781123-4 2013 RESULTS: During the immune response, pro-inflammatory phase, parenteral hydroxocobalamin (HOCbl) treatment partially inhibits hepatic, but not lung, iNOS mRNA and promotes lung eNOS mRNA, but attenuates the LPS hepatic rise in eNOS mRNA, whilst paradoxically promoting high iNOS/eNOS protein translation, but relatively moderate NO production. Hydroxocobalamin 72-88 nitric oxide synthase 2, inducible Mus musculus 149-153 23781123-4 2013 RESULTS: During the immune response, pro-inflammatory phase, parenteral hydroxocobalamin (HOCbl) treatment partially inhibits hepatic, but not lung, iNOS mRNA and promotes lung eNOS mRNA, but attenuates the LPS hepatic rise in eNOS mRNA, whilst paradoxically promoting high iNOS/eNOS protein translation, but relatively moderate NO production. Hydroxocobalamin 72-88 nitric oxide synthase 2, inducible Mus musculus 274-278 23781123-4 2013 RESULTS: During the immune response, pro-inflammatory phase, parenteral hydroxocobalamin (HOCbl) treatment partially inhibits hepatic, but not lung, iNOS mRNA and promotes lung eNOS mRNA, but attenuates the LPS hepatic rise in eNOS mRNA, whilst paradoxically promoting high iNOS/eNOS protein translation, but relatively moderate NO production. Hydroxocobalamin 90-95 nitric oxide synthase 2, inducible Mus musculus 149-153 23781123-4 2013 RESULTS: During the immune response, pro-inflammatory phase, parenteral hydroxocobalamin (HOCbl) treatment partially inhibits hepatic, but not lung, iNOS mRNA and promotes lung eNOS mRNA, but attenuates the LPS hepatic rise in eNOS mRNA, whilst paradoxically promoting high iNOS/eNOS protein translation, but relatively moderate NO production. Hydroxocobalamin 90-95 nitric oxide synthase 2, inducible Mus musculus 274-278 23781123-5 2013 HOCbl/NOS/ NO regulation is reciprocally associated with lower 4 h expression of TNF-alpha, IL-1beta, COX-2, and lower circulating TNF-alpha, but not IL-6. Hydroxocobalamin 0-5 tumor necrosis factor Mus musculus 81-90 23781123-5 2013 HOCbl/NOS/ NO regulation is reciprocally associated with lower 4 h expression of TNF-alpha, IL-1beta, COX-2, and lower circulating TNF-alpha, but not IL-6. Hydroxocobalamin 0-5 interleukin 1 beta Mus musculus 92-100 23781123-5 2013 HOCbl/NOS/ NO regulation is reciprocally associated with lower 4 h expression of TNF-alpha, IL-1beta, COX-2, and lower circulating TNF-alpha, but not IL-6. Hydroxocobalamin 0-5 cytochrome c oxidase II, mitochondrial Mus musculus 102-107 23781123-5 2013 HOCbl/NOS/ NO regulation is reciprocally associated with lower 4 h expression of TNF-alpha, IL-1beta, COX-2, and lower circulating TNF-alpha, but not IL-6. Hydroxocobalamin 0-5 tumor necrosis factor Mus musculus 131-140 23781123-6 2013 In resolution, 24 h after LPS, HOCbl completely abrogates a major late mediator of sepsis mortality, high mobility group box 1 (HMGB1) mRNA, inhibits iNOS mRNA, and attenuates LPS-induced hepatic inhibition of eNOS mRNA, whilst showing increased, but still moderate, NOS activity, relative to LPS only. Hydroxocobalamin 31-36 high mobility group box 1 Mus musculus 128-133 23781123-6 2013 In resolution, 24 h after LPS, HOCbl completely abrogates a major late mediator of sepsis mortality, high mobility group box 1 (HMGB1) mRNA, inhibits iNOS mRNA, and attenuates LPS-induced hepatic inhibition of eNOS mRNA, whilst showing increased, but still moderate, NOS activity, relative to LPS only. Hydroxocobalamin 31-36 nitric oxide synthase 2, inducible Mus musculus 150-154 21497120-11 2011 These results concur with the observed phenotype of patients with the cblC disorder and their sometimes poor response to treatment with hydroxocobalamin. Hydroxocobalamin 136-152 Cbl proto-oncogene C Homo sapiens 70-74 22429804-9 2012 Major forms of B12 present in beef meat include adenosine cobalamin (AdoCbl) and in smaller quantities hydroxycobalamin (OHCbl). Hydroxocobalamin 103-119 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 15-18 22429804-9 2012 Major forms of B12 present in beef meat include adenosine cobalamin (AdoCbl) and in smaller quantities hydroxycobalamin (OHCbl). Hydroxocobalamin 121-126 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 15-18 22429804-10 2012 Major forms of vitamin B12 present in beef liver include OHCbl (48.2%), AdoCbl (33.8%), methylocobalamin (MeCbl, 16.3%), and cyanocobalamin (CNCbl, 1.7%). Hydroxocobalamin 57-62 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 23-26 21922568-8 2011 The final major Cbl(III) product observed (nitrocobalamin or hydroxycobalamin) depends on the solution pH. Hydroxocobalamin 61-77 Cbl proto-oncogene Homo sapiens 16-19 21130828-2 2011 The reduced form of vitamin B(12), cob(I)alamin {Cbl(I)}, obtained by reduction of hydroxocobalamin (OH-Cbl) with e.g. sodium borohydride, is one of the most powerful nucleophiles known. Hydroxocobalamin 83-99 metabolism of cobalamin associated B Homo sapiens 35-38 21130828-2 2011 The reduced form of vitamin B(12), cob(I)alamin {Cbl(I)}, obtained by reduction of hydroxocobalamin (OH-Cbl) with e.g. sodium borohydride, is one of the most powerful nucleophiles known. Hydroxocobalamin 83-99 Cbl proto-oncogene Homo sapiens 49-52 21130828-2 2011 The reduced form of vitamin B(12), cob(I)alamin {Cbl(I)}, obtained by reduction of hydroxocobalamin (OH-Cbl) with e.g. sodium borohydride, is one of the most powerful nucleophiles known. Hydroxocobalamin 83-99 Cbl proto-oncogene Homo sapiens 104-107 19328848-4 2009 Hydroxocobalamin (OH-Cbl), cobinamide, and dicyanocobinamide (CN(2)-Cbi) potently inhibited all isoforms, whereas cyanocobalamin, methylcobalamin, and adenosylcobalamin had much less effect. Hydroxocobalamin 0-16 Casitas B-lineage lymphoma Mus musculus 21-24 20490923-10 2011 The long-term treatment of CblE, CblG, and CblD-variant-1 defects consists of parenterally administered hydroxocobalamin and orally administered folate and betaine supplements, whereas patients with MTHFR deficiency require long-term oral folate and betaine supplements. Hydroxocobalamin 104-120 metabolism of cobalamin associated D Homo sapiens 43-47 19421072-10 2009 The nitric oxide scavenger hydroxocobalamin and the Na+-K+ ATPase inhibitor ouabain abolished the responses to bradykinin and light. Hydroxocobalamin 27-43 kininogen 1 Homo sapiens 111-121 21071249-4 2011 Using solution-phase intrinsic fluorescence and label-free, real-time surface plasmon resonance (SPR), MMACHC bound cyanocobalamin and hydroxycobalamin with similar low micromolar affinities (K(D) 6.4 and 9.8 muM, respectively); adenosylcobalamin and methylcobalamin also shared similar binding affinities for MMACHC (K(D) 1.7 and 1.4 muM, respectively). Hydroxocobalamin 135-151 metabolism of cobalamin associated C Homo sapiens 103-109 18584368-6 2008 RESULTS: The remainder spectrum appears to be a methemoglobin variant quantitatively dependant on the amount of hydroxocobalamin added to the hemoglobin solution and the presence of oxygen. Hydroxocobalamin 112-128 hemoglobin subunit gamma 2 Homo sapiens 48-61 18584368-9 2008 This is the first study to document methemoglobin formation caused by hydroxocobalamin. Hydroxocobalamin 70-86 hemoglobin subunit gamma 2 Homo sapiens 36-49 15066907-8 2004 The guanylyl cyclase inhibitor ODQ and the NO scavenger hydroxocobalamin induced a larger shift of the bradykinin CRC than the NO synthase inhibitor L-NAME, although all three inhibitors equally suppressed bradykinin-induced cGMP responses. Hydroxocobalamin 56-72 kininogen 1 Homo sapiens 103-113 16227032-1 2005 OBJECTIVE: To evaluate prenatal treatment with hydroxycobalamin (OH-Cbl) in a pregnancy at risk for a severe form of the cobalamin C defect and postnatal treatment of the affected child. Hydroxocobalamin 47-63 Cbl proto-oncogene Homo sapiens 68-71 17957493-4 2008 All the mut (0) and some of the cblB patients had the most severe clinical and biochemical manifestations, displaying non-inducible propionate incorporation in the presence of hydroxocobalamin (OHCbl) in vitro and high plasma odd-numbered long-chain fatty acid (OLCFA) concentrations under dietary therapy. Hydroxocobalamin 176-192 Cbl proto-oncogene B Homo sapiens 32-36 15066907-8 2004 The guanylyl cyclase inhibitor ODQ and the NO scavenger hydroxocobalamin induced a larger shift of the bradykinin CRC than the NO synthase inhibitor L-NAME, although all three inhibitors equally suppressed bradykinin-induced cGMP responses. Hydroxocobalamin 56-72 kininogen 1 Homo sapiens 206-216 15061579-5 2004 Hydroxocobalamin therapy increased serum vitamin B12 concentrations 14-fold (p < 0.001) and reduced plasma tHcy by 23% from 29.7 +/- 2.9 to 22.8 +/- 2.5 micromol/L (p < 0.01); serum methylmalonate decreased by one-third (p < 0.05). Hydroxocobalamin 0-16 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 49-52 8869664-3 1996 In the present study we validate the use of vitamin B12 (hydroxocobalamin, 1 mg ml-1) as an internal standard to determine this dilution, since its strong red colour lends itself to spectroscopic measurement by a capillary tube system requiring only 3 microliter per sample. Hydroxocobalamin 57-73 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 52-55 12466224-7 2002 Hydroxycobalamin, a NO scavenger, but not superoxide dismutase and catalase, enzymes that metabolize superoxide and hydrogen peroxide, respectively, abolished the inhibitory effect of DEA/NO and SIN-1, indicating that they inhibit DA uptake through a mechanism related to the production of NO but unrelated to the formation of peroxynitrite. Hydroxocobalamin 0-16 MAPK associated protein 1 Homo sapiens 195-200 10491133-8 1999 A type II change (red shift) of the Soret band (405 nm --> 413-419 nm) was observed when wild-type HO-2 was treated with sodium nitroprusside (SNP), S-nitroglutathione (GSNO), S-nitroso-N-acetylpenicillamine (SNAP) or 3-morpholinosydnonimine (SIN-1); the NO scavenger, hydroxocobalamin (HCB) prevented the shift. Hydroxocobalamin 272-288 heme oxygenase 2 Homo sapiens 102-106 10491133-8 1999 A type II change (red shift) of the Soret band (405 nm --> 413-419 nm) was observed when wild-type HO-2 was treated with sodium nitroprusside (SNP), S-nitroglutathione (GSNO), S-nitroso-N-acetylpenicillamine (SNAP) or 3-morpholinosydnonimine (SIN-1); the NO scavenger, hydroxocobalamin (HCB) prevented the shift. Hydroxocobalamin 290-293 heme oxygenase 2 Homo sapiens 102-106 10491133-12 1999 Again, trapping NO with HCB blocked HO-2 inactivation. Hydroxocobalamin 24-27 heme oxygenase 2 Homo sapiens 36-40 10399092-0 1999 Progressive neurological deterioration and MRI changes in cblC methylmalonic acidaemia treated with hydroxocobalamin. Hydroxocobalamin 100-116 Cbl proto-oncogene C Homo sapiens 58-62 9755062-7 1998 The ability of SNP to induce HO-1 in L6.G8 cells was reduced by coincubation with hydroxocobalamin, a known nitric oxide (NO) scavenger, suggesting that NO itself may be involved in HO-1 gene stimulation. Hydroxocobalamin 82-98 heme oxygenase 1 Rattus norvegicus 29-33 9755062-7 1998 The ability of SNP to induce HO-1 in L6.G8 cells was reduced by coincubation with hydroxocobalamin, a known nitric oxide (NO) scavenger, suggesting that NO itself may be involved in HO-1 gene stimulation. Hydroxocobalamin 82-98 heme oxygenase 1 Rattus norvegicus 182-186 9470012-0 1998 Biochemical and clinical response to hydroxocobalamin versus cyanocobalamin treatment in patients with methylmalonic acidemia and homocystinuria (cblC). Hydroxocobalamin 37-53 Cbl proto-oncogene C Homo sapiens 146-150 9247460-0 1997 Normalization of plasma vitamin B12 concentration by intranasal hydroxocobalamin in vitamin B12-deficient patients. Hydroxocobalamin 64-80 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 32-35 14691197-5 2004 In contrast, complete blockade of bradykinin-induced relaxation was obtained when we combined the nonselective BK(Ca) and intermediate-conductance (IK(Ca)) Ca2+-dependent K+ channel blocker charybdotoxin and apamin with hydroxocobalamin. Hydroxocobalamin 220-236 kininogen 1 Homo sapiens 34-44 14691197-7 2004 Inhibition of inwardly rectifying K+ channels (K(IR)) and Na+/K+-ATPase (with BaCl2 and ouabain, respectively) shifted the bradykinin concentration-response curve 10-fold to the right but did not exert an additional effect in the presence of hydroxocobalamin. Hydroxocobalamin 242-258 killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 Homo sapiens 47-52 14691197-7 2004 Inhibition of inwardly rectifying K+ channels (K(IR)) and Na+/K+-ATPase (with BaCl2 and ouabain, respectively) shifted the bradykinin concentration-response curve 10-fold to the right but did not exert an additional effect in the presence of hydroxocobalamin. Hydroxocobalamin 242-258 kininogen 1 Homo sapiens 123-133 12444907-3 2002 The NO synthase inhibitor N (G)-nitro-L-arginine methyl ester (L-NAME; 100 microM) and the NO scavenger hydroxocobalamin (200 microM) each produced a rightward shift in the bradykinin concentration-response curve [pEC(50): L-NAME, 8.9+/-0.1 ( n =6; P <0.01); hydroxocobalamin, 8.3+/-0.2, ( n =6; P <0.001)]. Hydroxocobalamin 104-120 kininogen 1 Bos taurus 173-183 12359636-12 2002 Apamin (100 nM) combined with iberiotoxin (100 nM) also reduced the response to bradykinin in the presence of hydroxocobalamin or L-NAME. Hydroxocobalamin 110-126 kininogen 1 Bos taurus 80-90 10382556-9 1999 Cobalt is an essential element necessary for the formation of vitamin B12 (hydroxocobalamin); however, excessive administration of this trace element produces goiter and reduced thyroid activity. Hydroxocobalamin 75-91 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 70-73 1687159-3 1991 One was classified as a Cbl A variant and was responsive to hydroxocobalamin therapy in vitro and in vivo. Hydroxocobalamin 60-76 Cbl proto-oncogene Homo sapiens 24-27 7909321-1 1994 The mut0 mutation resulting in methylmalonyl CoA mutase (MCM) apoenzyme deficiency and methylmalonic aciduria is characterized by undetectable enzyme activity in cell extracts and low incorporation of propionate into cultured cells which is not stimulated by hydroxycobalamin. Hydroxocobalamin 259-275 methylmalonyl-CoA mutase Homo sapiens 57-60 8492341-6 1993 Pharmacokinetic parameters of hydroxocobalamin were best defined in the group who received both antidotes: t1/2 (alpha), 0.52 h; t1/2 (beta), 2.83 h; Vd (beta), 0.24 L/kg; and mean peak serum concentration 753 mcg/mL (560 mumol/L) at 0-50 minutes after completion of infusion. Hydroxocobalamin 30-46 CD2 molecule Homo sapiens 107-122 1351201-0 1992 IGE-mediated reaction to hydroxocobalamin injection in patient with pernicious anaemia. Hydroxocobalamin 25-41 immunoglobulin heavy constant epsilon Homo sapiens 0-3 8415778-0 1993 Transcobalamin II mediated delivery of albumin-bound hydroxocobalamin to human liver cells. Hydroxocobalamin 53-69 transcobalamin 2 Homo sapiens 0-17 8415778-3 1993 In the presence of transcobalamin II, a 4.5-fold increase in cellular uptake occurred, but this amount was less than when hydroxocobalamin or cyanocobalamin were added to transcobalamin II. Hydroxocobalamin 122-138 transcobalamin 2 Homo sapiens 19-36 8415778-4 1993 These results indicate that albumin, by binding hydroxocobalamin, can alter the dynamics of binding to transcobalamin II and the subsequent cellular incorporation of this form of the vitamin. Hydroxocobalamin 48-64 transcobalamin 2 Homo sapiens 103-120 2033045-1 1991 Vitamin B12 (hydroxycobalamin) is endocytosed by mammalian cells as a complex with transcobalamin II and then processed to free B12 in lysosomes. Hydroxocobalamin 13-29 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 8-11 2033045-1 1991 Vitamin B12 (hydroxycobalamin) is endocytosed by mammalian cells as a complex with transcobalamin II and then processed to free B12 in lysosomes. Hydroxocobalamin 13-29 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 128-131 1701451-1 1990 Treatment of rats with the vitamin B12 analogue hydroxy-cobalamin[c-lactam] (HCCL) impairs methylmalonyl-CoA mutase function and leads to methylmalonic aciduria due to intracellular accumulation of propionyl and methylmalonyl-CoA. Hydroxocobalamin 48-65 methylmalonyl-CoA mutase Rattus norvegicus 91-115 3589492-5 1987 Hydroxocobalamin was the main form of Cbl in the lysosomal fraction. Hydroxocobalamin 0-16 Cbl proto-oncogene Homo sapiens 38-41 3340005-4 1988 After administration of hydroxycobalamin to vitamin B12-deficient subjects, homocysteine levels decreased to normal (-49%, 12.2 +/- 1.5 mumol/L, P less than .0001, n = 20). Hydroxocobalamin 24-40 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 52-55 35549585-0 2022 Elevated methemoglobin levels in patients treated with hydroxocobalamin: a case series and in-vitro analysis. Hydroxocobalamin 55-71 hemoglobin subunit gamma 2 Homo sapiens 9-22 35549585-4 2022 We observed elevated methemoglobin (MetHb) levels in several patients treated with OHCbl and sought to investigate the incidence of MetHb formation following administration of OHCbl. Hydroxocobalamin 83-88 hemoglobin subunit gamma 2 Homo sapiens 21-34 3338997-2 1988 A vitamin B12-binding protein (haptocorrin) from chicken serum has been purified to homogeneity by photodissociative affinity chromatography and characterized by gel electrophoresis and UV-visible spectrophotometry of its aquocobalamin, hydroxocobalamin, and cyanocobalamin complexes. Hydroxocobalamin 237-253 transcobalamin 1 Homo sapiens 31-42 6774168-2 1980 Transfusion of hydroxocobalamin (OH-Cbl) bound to normal plasma temporarily restored granulocyte bactericidal activity and increased cellular levels of the cobalamin coenzymes. Hydroxocobalamin 15-31 Cbl proto-oncogene Homo sapiens 36-39 6143788-0 1984 Effects of cobalt or hydroxycobalamin supplementation on vitamin B-12 content and (S)-methylmalonyl-CoA mutase activity of tissue from cobalt-depleted sheep. Hydroxocobalamin 21-37 methylmalonyl-CoA mutase, mitochondrial Ovis aries 86-110 6692038-1 1984 Hydroxocobalamin (OH-Cbl), when used to treat vitamin B12 deficiency, is better retained by the body than is cyanocobalamin (CN-Cbl), but the availability to cells has not been studied systematically. Hydroxocobalamin 0-16 Cbl proto-oncogene Homo sapiens 21-24 33023511-10 2020 After being diagnosed, she was treated with intramuscular 1 mg hydroxycobalamin (OH-Cbl) every day for 2 months. Hydroxocobalamin 63-79 Cbl proto-oncogene Homo sapiens 84-87 36882-1 1979 We have examined the effect of addition of hydroxocobalamin to growth medium on the activity of the adenosylcobalamin-requiring enzyme methylmalonyl CoA mutase in normal human fibroblasts and in mutant human fibroblasts derived from patients with inherited methylmalonicacidemia. Hydroxocobalamin 43-59 methylmalonyl-CoA mutase Homo sapiens 135-159 963297-1 1976 The uptake of 57Co-cyanocobalamin (CN-Cbl) and its conversion to 5-deoxyadenosylcobalamin (Ado-Cbl), methylcobalamin (Me-Cbl), and hydroxocobalamin (OH-Cbl) has been studied in phytohemagglutinin (PHA)-transformed lymphocytes from normal subjects and patients with patients with pernicious anemia. Hydroxocobalamin 131-147 Cbl proto-oncogene Homo sapiens 38-41 32754920-15 2021 CONCLUSION: Although similar at first, cblA patients respond to hydroxocobalamin treatment, subsequently show significantly lower levels of MMA and a milder course than mut patients. Hydroxocobalamin 64-80 metabolism of cobalamin associated A Homo sapiens 39-43 33011041-0 2020 Elevated Methemoglobin Levels in a Patient Treated with Hydroxocobalamin After Suspected Cyanide Exposure. Hydroxocobalamin 56-72 hemoglobin subunit gamma 2 Homo sapiens 9-22 33050187-4 2020 Previously, we developed an in vitro model of cobalamin deficiency in normal human astrocytes (NHA) by culturing the cells with c-lactam of hydroxycobalamin (c-lactam OH-Cbl). Hydroxocobalamin 140-156 Cbl proto-oncogene Homo sapiens 170-173 5126165-0 1971 Antibody to transcobalamin II and B12 binding capacity in patients treated with hydroxocobalamin. Hydroxocobalamin 80-96 transcobalamin 2 Homo sapiens 12-29 5488577-0 1970 [Occurrence of antibodies against transcobalamin II in relation to the number of and the intervals between depot therapy with hydroxocobalamin]. Hydroxocobalamin 126-142 transcobalamin 2 Homo sapiens 34-51 33754111-2 2021 Hydroxocobalamin (HCB) affects NO-mediated vasoplegia as (1) a direct inhibitor of nitric oxide synthase (NOS), thereby decreasing its production, and (2) by binding directly to NO and acting as a scavenger. Hydroxocobalamin 0-16 nitric oxide synthase 2 Homo sapiens 83-104 33754111-2 2021 Hydroxocobalamin (HCB) affects NO-mediated vasoplegia as (1) a direct inhibitor of nitric oxide synthase (NOS), thereby decreasing its production, and (2) by binding directly to NO and acting as a scavenger. Hydroxocobalamin 18-21 nitric oxide synthase 2 Homo sapiens 83-104 32815652-1 2020 BACKGROUND: In humans, absorption and tissue retention rates of intramuscularly administered hydroxocobalamin (OH-Cbl) are superior compared to cyanocobalamin (CN-Cbl). Hydroxocobalamin 93-109 Cbl proto-oncogene Homo sapiens 114-117 30871199-3 2019 In the present study we have used the H2S scavenger and vitamin B12 analog hydroxycobalamin (Cbl) as a new tool to investigate the involvement of endogenous H2S in CB oxygen sensing. Hydroxocobalamin 75-91 Cbl proto-oncogene Rattus norvegicus 93-96 32071835-4 2020 We report three adult siblings with late-onset cblC disease, and their biochemical and clinical responses to high-dose hydroxocobalamin. Hydroxocobalamin 119-135 Cbl proto-oncogene C Homo sapiens 47-51 32071835-13 2020 This study highlights the importance of evaluating intracellular cobalamin metabolism in adults with neuropsychiatric manifestations and/or thromboembolic events, and demonstrates that high-dose hydroxocobalamin achieves rapid and sustainable metabolic control and improvement in neuropsychiatric outcomes in adults with late-onset cblC disease. Hydroxocobalamin 195-211 Cbl proto-oncogene C Homo sapiens 332-336 32440343-5 2020 We therefore treated rats with three daily doses of methylcobalamin (CH3Cbl) or hydroxocobalamin (OHCbl), a cofactor for methionine synthase, or L-methionine, followed by TCE (16 mg/kg) to determine if they could alleviate the formic aciduria. Hydroxocobalamin 80-96 5-methyltetrahydrofolate-homocysteine methyltransferase Rattus norvegicus 121-140 31350635-7 2019 When hydroxocobalamin (OHCbl) or cob(II)alamin is bound to TsrM, a reductant is required to convert it to cob(I)alamin, which can acquire a methyl group directly from SAM. Hydroxocobalamin 5-21 TSRM Homo sapiens 59-63 31350635-7 2019 When hydroxocobalamin (OHCbl) or cob(II)alamin is bound to TsrM, a reductant is required to convert it to cob(I)alamin, which can acquire a methyl group directly from SAM. Hydroxocobalamin 23-28 TSRM Homo sapiens 59-63 31350635-8 2019 Our studies suggest that TsrM uses an external reductant to prime its reaction by converting bound OHCbl or cob(II)alamin to MeCbl, and to regenerate the MeCbl form of the cofactor upon adventitious oxidation of the cob(I)alamin intermediate to cob(II)alamin. Hydroxocobalamin 99-104 TSRM Homo sapiens 25-29 31187494-5 2019 Here, we outline the pathophysiology of vasodilatory shock, describe the rationale for vitamin B12 (hydroxocobalamin) in vasodilatory shock, and identify literature evaluating its use in vasoplegic states. Hydroxocobalamin 100-116 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 95-98 29573551-7 2018 Following the administration of 5 g of i.v.hydroxocobalamin, the patient had a profound improvement in arterial blood pressure, with subsequent discontinuation of the vasopressin infusion and rapid reduction of norepinephrine infusion from 20 to 2 mug/min. Hydroxocobalamin 43-59 arginine vasopressin Homo sapiens 167-178 29205285-5 2018 Prior to attachment to mAbs, the vitamin B12 needs to be in its active form of hydroxocobalamin. Hydroxocobalamin 79-95 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 41-44 29205285-6 2018 During culture media preparation, storage and cell culture processing, cyanocobalamin, the chemical form of vitamin B12 added to media, is converted to hydroxocobalamin by white fluorescence light (about 50% degradation in 11-14 days at room temperature and with room light intensity about 500-1,000 lux) and by short-wavelength visible light (400-550 nm). Hydroxocobalamin 152-168 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 116-119 29205285-8 2018 Our findings suggests that the intensity of pink color depends on concentrations of both free sulfhydryl groups on reduced mAb and hydroxocobalamin, the active form of vitamin B12 . Hydroxocobalamin 131-147 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 176-179